Prospective, randomized, open label phase II study to assess efficacy and safety of Macugen® (pegaptanib 0.3 mg intravitreal injections) plus panretinal photocoagulation (PRP) and PRP (monotherapy) in the treatment of patients with high risk proliferative diabetic retinopathy

Coordinator

José Cunha-Vaz

Start

February 2010

End

July 2011

Centres and/or Units

4C - Coimbra Coordinating Centre for Clinical Research

Research area

Proliferative Diabetic Retinopathy

Projects by department: